6533b832fe1ef96bd129afaf

RESEARCH PRODUCT

CAPD + hemoperfusion once a week in the management of children with end-stage renal disease

S MaioneN. G. De SantoVaccaro FCarmelo GiordanoG. CapodicasaManzo MCapasso Giovambattista

subject

Malemedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyBiomedical EngineeringUrologyMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologyEnd stage renal diseasePeritoneal dialysisBiomaterials03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePeritoneal Dialysis Continuous AmbulatoryHumansMedicinePlatelet activationChildIntensive care medicineDialysisCreatininebusiness.industryLiterGeneral MedicineHemoperfusionUric AcidHemoperfusionchemistryCreatinineKidney Failure ChronicUric acidFemalebusinessPeritoneal Dialysis

description

With hemoperfusion there is a sharp decline in the solute concentration of the blood compartment, but immediately after HP the concentration of these substances rises to the original level (post-Hp rebound). It may be inferred that the result would be better and the rebound phenomenon less marked if hemoperfusion could be combined with a continuous dialysis system such as CAPD. The study was performed in 3 children of our CAPD programm. All patients were dialysed with 5 daily exchange each of one liter. The patients underwent at 2-hours hemoperfusion with a charcoal column (Gambro Adsorba 150 c) once a week. The data obtained with this form of treatment are indicative for a: significant increase of weekly clearance for uric acid and creatinine. low urea generation rate far 1–3 days after HP. low post-Hp rebound and reduced platelet count but not platelet activation.

http://www.scopus.com/inward/record.url?eid=2-s2.0-0020912501&partnerID=MN8TOARS